In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candid… Read more
Market Cap & Net Worth: In8bio Inc (INAB)
In8bio Inc (NASDAQ:INAB) has a market capitalization of $18.65 Million ($18.65 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29949 globally and #9894 in its home market, demonstrating a 7.91% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying In8bio Inc's stock price $1.91 by its total outstanding shares 9766132 (9.77 Million).
In8bio Inc Market Cap History: 2021 to 2026
In8bio Inc's market capitalization history from 2021 to 2026. Data shows change from $42.87 Million to $18.65 Million (-30.05% CAGR).
Index Memberships
In8bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #775 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2472 of 3165 |
Weight: In8bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
In8bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how In8bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of INAB by Market Capitalization
Companies near In8bio Inc in the global market cap rankings as of March 18, 2026.
Key companies related to In8bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
In8bio Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, In8bio Inc's market cap moved from $42.87 Million to $ 18.65 Million, with a yearly change of -30.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $18.65 Million | -18.38% |
| 2025 | $22.85 Million | +809.80% |
| 2024 | $2.51 Million | -81.36% |
| 2023 | $13.48 Million | -40.26% |
| 2022 | $22.56 Million | -47.38% |
| 2021 | $42.87 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of In8bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.65 Million USD |
| MoneyControl | $18.65 Million USD |
| MarketWatch | $18.65 Million USD |
| marketcap.company | $18.65 Million USD |
| Reuters | $18.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.